Page 11 - Bharat Biotech

India to miss July-end Covid vaccination target as Bharat Biotech lags

The government had been counting on deliveries of 60 million to 70 million Covaxin doses monthly from July or August.

Brazil suspends clinical trials of Covaxin after termination of agreement

Brazil has suspended the clinical studies of Bharat Biotech's Covaxin following termination of the company's agreement with its partner there, the South American Country's health regulator said

Bharat Biotech axes Covid vaccine deal with Brazil's Precisa: Statement

Bharat's statement said it will continue to work with Brazilian health care regulator Anvisa to obtain all required approvals for the use of Covaxin in the country

Bharat Biotech's Bengaluru unit has overcome glitches, says V K Paul

Bharat Biotech is hoping to manufacture 1 billion doses per annum by the end of this year.

Process to receive WHO pre-qualification for Covaxin on, says govt

Covishield manufactured by the Serum Institute of India (SII) has received the WHO pre-qualification, while the process of pre-qualification for Bharat Biotech's Covaxin is going on

Bharat Biotech had agreed to offer vaccine at reasonable rates to Govt: MoH

ICMR has spent Rs 35 cr on Covaxin clinical trials

WHO assessing Covaxin data for EUL; decision date 'to be confirmed'

WHO, which is currently reviewing Bharat Biotech's application for an Emergency Use Listing of its Covid-19 vaccine Covaxin, has said it is assessing the data of the jab

New price good, but Rs 250 a dose better: Covid-19 vaccine makers

Centre has ordered 660 mn doses, expected to be supplied between Aug & Dec

Small contract manufacturers wait to take a shot at Covid vaccines

A host of lesser-known vaccine makers are eyeing contract manufacturing opportunities for global and domestic majors

Related party risks

Bharat Bio-Brazil investigation reveals dangers of offshore agencies

Best of BS Opinion: Related party risks, a new green wave of growth & more

Here are the best of Business Standard's opinion pieces for Wednesday

Bharat Biotech-Brazil row: Covaxin nod under controlled conditions

The agency said the suspension - which put the EUA application on ice - was due to missing data from the vaccine's clinical trials

A bottleneck in the vaccine chain

Prosenjit Datta points to a possible crisis as the government moves to improve supplies of Covid vaccines: inadequate testing facilities to handle those volumes

Covaxin 77.8% effective against symptomatic Covid-19: Bharat Biotech

The company claimed Covaxin is the first to report promising efficacy against asymptomatic infections based on qPCR testing that will help in reducing disease transmission

Covaxin 77.8% effective against symptomatic Covid-19, says Bharat Biotech

The analysis also found that Covaxin is 93.4 per cent effective against severe symptomatic Covid-19

Decision on Covaxin approval by August second week: WHO chief scientist

Developed by Bharat Biotech and the ICMR, Covaxin was approved by the Indian drug controller in January, and has been in use since

Decoded: Why Brazilian govt is under scrutiny over Bharat Biotech vaccine

The Brazilian media has reported that though Bharat Biotech initially quoted a price of $1.34 per dose, the Brazilian govt agreed to pay $15 per shot, having ignored Pfizer's offer at a lower price

Haven't received any payment from Brazilian health ministry: Bharat Biotech

Madison Biotech was founded by Krishna Ella in 2020 for external R&D, sales and marketing of vaccines

Brazil suspends $324-mn Covid-19 vaccine deal with Bharat Biotech

The deal to buy 20 million doses of Bharat Biotech's Covaxin shot has become a headache for Bolsonaro after whistleblowers went public with alleged irregularities

Covaxin effectively neutralises Alpha, Delta variants of Covid, says NIH

Covaxin, developed by Bharat Biotech in collaboration with the ICMR, effectively neutralises both Alpha and Delta variants of coronavirus, US' National Institute of Health has said